What actually happens when you stop a GLP-1 medication

What did @drjencaudle actually say?

Pretty straightforward stuff, actually. Dr. Caudle runs through five things that happen when you stop GLP-1 medications like semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss). Her list: blood sugar goes up, appetite comes back, GI side effects go away, weight loss benefit disappears, and cardiovascular benefits stop. She closes with the reasonable caveat that stopping or starting is "between you and your doctor." No wild claims, no miracle language. Just a clinical rundown from someone who appears to actually see patients.

She correctly names semaglutide as the active ingredient in both Ozempic and Wegovy, which is accurate. She keeps her language appropriately hedged, saying appetite "may" increase and blood sugar "will likely" rise. That kind of measured phrasing matters in this space.

Does the science back this up?

Yes, with some important nuance she glosses over. The evidence on GLP-1 discontinuation is now reasonably solid, and most of what she says tracks with published trial data. The caveat is that the cardiovascular benefits point is more complicated than she makes it sound.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed participants after semaglutide was stopped. Within one year, two-thirds of the weight lost during the trial was regained. Appetite and hunger scores returned toward baseline. That directly supports her claim that appetite returns and weight comes back.

On blood sugar: this is well-established pharmacology. GLP-1 receptor agonists work partly by stimulating insulin secretion in a glucose-dependent manner. Remove the drug, remove that effect. The American Diabetes Association's 2024 Standards of Care confirm that glycemic control typically worsens after discontinuation in people with type 2 diabetes.

The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed a 20% reduction in major adverse cardiovascular events with semaglutide in people with obesity but without diabetes. What happens to that benefit after stopping is not yet well-characterized, which is a gap Dr. Caudle doesn't flag.

What did they get wrong (or right)?

She got most of it right. The one place I'd push back is the cardiovascular benefits section. She says when you stop, you "will not have" those benefits, as if the benefit simply switches off. That's probably true, but the honest answer is we don't know the trajectory. The SELECT trial didn't study discontinuation outcomes specifically. There's a real question about whether some residual cardiovascular benefit persists, decays gradually, or vanishes immediately. Presenting it as a clean on/off is an oversimplification.

She also doesn't mention that not everyone regains all the weight. The STEP 1 extension showed about one-third of participants kept more of their weight off. Her phrasing, "many people who stop these medications do gain the weight back," is accurate, but it slightly understates the variability. Some people do maintain meaningful loss, especially if they've made behavioral changes alongside medication use.

On the side effects point, she's correct. GI symptoms from GLP-1s are drug-mediated and typically resolve after stopping. That's well-supported in the published adverse event data from STEP and SUSTAIN trial programs.

What should you actually know?

GLP-1 medications are not permanent fixes, and stopping them has real, documented consequences. That's the honest message here, and Dr. Caudle delivers it without sugarcoating. The biology of obesity means the body actively defends its higher weight set point. That's not a willpower failure. It's documented endocrinology.

If you're stopping because of cost, access, or side effects, those are legitimate reasons and your prescriber should know. Abrupt discontinuation in a person with type 2 diabetes may require adjustments to other medications to prevent hyperglycemia. That's not optional information, and Dr. Caudle does flag it briefly.

The cardiovascular benefit question deserves more attention than it typically gets in short-form content. If the reason you're on a GLP-1 includes cardiovascular risk reduction, that's a different clinical calculation than weight loss alone. Talk to your doctor about what stopping means for your specific risk profile, not just your scale number.